WHAT IS PT-141
When attraction and desire don’t match
- Sexual responsiveness is often thought of as a physical experience, but desire starts in the brain.² ³
- Many men and women still feel attraction and connection, but notice desire doesn’t come as naturally as it once did.⁴
- PT-141 is a peptide that may support brain pathways that initiate arousal and sexual desire.¹
- Unlike therapies that focus on blood flow, PT-141 may act through central signaling pathways involved with sexual responsiveness.⁷
- Designed for men and women seeking support for desire and intimacy.
- Compounded by licensed U.S. pharmacies.
PT-141 BENEFITS
A different approach to sexual wellness
- Most sexual health treatments focus primarily on blood flow and physical response, mainly for men.⁷
- PT-141 works differently by potentially supporting brain pathways involved in arousal and sexual desire for both men and women.¹
- Because desire involves both the mind and body, PT-141 may offer a unique approach for men and women seeking support for intimacy and responsiveness.¹
- Often explored by people who still feel attraction, but want desire and responsiveness to feel more natural again.¹
- Data suggests 25-30% of men don’t achieve their desired outcome with PDE5i medication (like Viagra or Cialis), offering a potential solution.¹³
- Available through clinician-guided care and compounded by licensed U.S. pharmacies.
PT-141 has been approved by the FDA for Hypoactive Sexual Desire Disorder (HSDD) for premenopausal women, but has not been approved by the FDA for use as sexual enhancement in men or post-menopausal women.
The Science of PT-141
Desire starts in the brain: While sexual wellness is often thought of as a physical experience, desire is influenced by signaling pathways in the brain. This signaling declines with age, impacting libido, desire, and overall brain health.¹⁰ ¹¹
A different approach: PT-141 works on brain pathways involved in sexual desire and arousal. Unlike therapies that primarily focus on blood flow, PT-141 is understood to cross the blood-brain barrier to potentially act on melanocortin pathways associated with sexual responsiveness, helping support the brain-body connection involved in intimacy.¹ ⁷
Why AgelessRx?
Personalized care guided by US-licensed clinicians
Backed by our Stanford PhD-led Research Team
Treatments are clinically vetted and clinician-reviewed
100% online, ongoing check-ins, and free shipping
Our customers think we’re excellent
-
Dave P.
I’d give 6 stars if possible!! I was skeptical. But no longer. The products are of highest quality and customer service is fast, convenient and thorough. Highly recommend!
-
Christina A.
No hidden fees, no monthly fees. I only pay for the medication itself. I can’t stop raving about AgelessRx because every other company I looked into was the complete opposite.
-
Kevin D.
Customer service is excellent and timely response. The research and development of this company is phenomenal. Very educational.
-
Brooke X.
Reliable source of quality products. Shipping is fast and follow up is quick, allowing for any questions or concerns to be addressed. I feel confident when using Ageless RX as a partner is my health & wellness journey.
-
Karey K.
They really care about making peoples lives more healthy and productive. The medical staff goes above and beyond to ensure your happy with your prescriptions.
-
Shelagh H.
Health providers are friendly and knowledgeable; made it easy to speak with them directly or to remotely ask a question. Highly recommend!
Ready to get started?
Start your free online visit now.
- 100% online medical assessment
- Free shipping and ongoing support
- Unlimited dosing adjustments and provider messaging
- On-demand use, taken as directed prior to sexual activity
- Compounded at US-licensed pharmacy
- Pause or cancel anytime
Code PT141INJ50: $149 for first month and FREE medical evaluation ($199/month after)
PT-141 Injections are not available in AL, AR, MN, & NC.
You will be automatically billed & sent refills based on your plan
You can pause or cancel at any time before your next shipment
The FDA has not approved or reviewed PT-141 for safety, efficacy, quality, or for any use, including the AgelessRx compounded product.
Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. See below for important safety information. Benefits outlined on AgelessRx.com are based on 3rd party studies. Medication is offered as a subscription service which you can cancel at any time. Actual product packaging may appear differently than shown.
FAQs
What is PT-141?
PT-141 (Bremelanotide) is a melanocortin receptor agonist peptide that works through the central nervous system to support sexual desire and arousal.1 It acts on pathways in the brain involved in sexual response rather than directly affecting blood flow.7
How does PT-141 work?
PT-141 activates melanocortin receptors in the brain associated with sexual motivation and arousal signaling. This may help enhance sexual interest, responsiveness, and satisfaction in some individuals.1
What benefits can I expect from PT-141?
Individual results vary, and benefits are not guaranteed. Some users may experience increased sexual desire and libido, improved arousal response, enhanced sexual satisfaction, and improved overall mood and motivation.1 2 7
See all FAQsImportant safety information and common side effects
Side effects
The most common side effects of PT-141 include:
- Nausea
- Facial flushing
- Headache
- Fatigue
- Temporary increase in blood pressure
- Mild irritation or sensitivity
These side effects are typically mild and often go away on their own within a week or two.
For a full list of side effects, please review Mayo Clinic’s Bremelanotide resources.
Potential drug interactions
PT-141 may have the following interactions with certain drugs:
- Naltrexone for alcohol or opioid use disorder
May decrease naltrexone levels and efficacy. - PDE-5 Inhibitors (sildenafil, tadalafil)
May increase the risk of priapism or prolonged erection, a medical emergency. - Potassium Citrate and Potassium Chloride
May increase risk of ulcerative colitis or stenotic lesions. - Antibiotics and Anti-Tuberculosis Agents
May decrease peak antibiotic levels.
Please read the full list of possible drug interactions with PT-141 (Bremelanotide).
Other important safety information
PT-141 is intended for adults only. Your prescriber may ask you for additional information if you have cardiovascular risk factors or severe liver or kidney disease.
Do not use PT-141 if you have uncontrolled high blood pressure or if you have significant heart dysfunction (ejection fraction <50% or NYHA Class 3 or greater).
Do not use PT-141 if you have an active cancer, or if you have had cancer within the last two years.
Do not use PT-141 if you are pregnant, breastfeeding, or planning to become pregnant or breastfeed. If you become pregnant during treatment, discontinue immediately and consult your OB.
Though rare, allergic reactions to PT-141 are still possible. If you notice any shortness of breath or swelling around your face, tongue, or throat after using PT-141, stop use and contact emergency services right away.
As with any prescription medication, the dose prescribed is for you and you alone. Do not, under any circumstances, allow anyone else to use your PT-141.
Show me the science.
All our claims are backed by science, and we’ve got the receipts.
| 1. A clinical review highlighting PT-141 as a melanocortin receptor agonist that improves sexual desire, arousal, and pleasure in women with hypoactive sexual desire disorder. | Neurol Int., 2022 |
| 2. A review highlighting PT-141 effects on female sexual desire by modulating central neurotransmitter pathways, particularly through increased dopamine release in the brain. | Camb Core, 2021 |
| 3. A large study demonstrating that declines in sexual desire, activity, and function in adults over 50 are associated with increased risk of adverse health outcomes, including chronic illness, cardiovascular disease, and cancer. | Arch Sex Behav., 2019 |
| 4. A review highlighting the role of PT-141 in regulating sexual behavior through actions in key brain regions. | Prog Neuro, 2013 |
| 5. A review outlining how neurotransmitters and hormones such as dopamine, serotonin, oxytocin, and cortisol interact to influence desire, arousal, orgasm, and overall sexual well-being, particularly under conditions of stress. | Journ Psy Health, 2026 |
| 6. A clinical review highlighting hypoactive sexual desire disorder (HSDD) as a common condition in women, driven by neuroendocrine imbalances and the effectiveness of PT-141 as a therapeutic. | J Midwifery Womens Health, 2022 |
| 7. A clinical evaluation highlighting the role of PT-141 in men, suggesting improvements in sexual function, satisfaction, and arousal through its effects on increased dopamine and blood flow. | Journ of Uro, 2024 |
| 8. A large study demonstrating that higher frequency of sexual activity is associated with reduced risk of all-cause and cancer mortality in middle-aged adults, suggesting sexual activity as an indicator of overall health. | The Journ of Sex Med, 2020 |
| 9. A study demonstrating that higher frequency of sexual activity is associated with reduced inflammatory markers and improved quality of life, particularly in older adults. | The Journ of Sex Med, 2017 |
| 10. A review highlighting that sexual behavior is regulated by complex interactions between neurotransmitter systems, particularly dopamine and serotonin, and emphasizing its critical role in overall health and quality of life. | Brain Behav. 2019 |
| 11. A study demonstrating that age-related declines in dopamine signaling are associated with reduced cognitive performance, suggesting that enhancing dopamine function may support brain health. | Amer Journ Sci, 1998 |
| 12. A review highlighting melanocortin signaling as a key regulator of immune function with demonstrated anti-inflammatory and immunomodulatory effects. | Front. Endocrinol, 2019 |
| 13. This review summarizes the clinical impact of PDE5 inhibitors for ED, highlighting one-third of patients fail to respond due to hormonal, vascular, psychological, or disease-related factors. | BMJ, 2006 |
